First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.
David J T CampbellDennis B CampbellYewande OgundejiFlora AuReed BeallPaul E RonksleyAmity E QuinnBraden J MannsBrenda R HemmelgarnMarcello TonelliEldon SpackmanPublished in: Diabetic medicine : a journal of the British Diabetic Association (2021)
With the addition of new classes of medications, healthcare providers who look after those with type 2 diabetes have more pharmaceutical options than ever. Most individuals continue to be prescribed metformin monotherapy. However, adherence is suboptimal, and drops off considerably within the first 3 months.